Society of Interventional Oncology Podcast

Episode 4: Ablation vs. Ablation + Combination Immune Therapy

Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice. Episode 4: Ablation vs. Ablation + Combination Immune Therapy Can combining ablation with immune therapy improve patient outcomes in liver cancer? Experts Gentry King and Isabel Newton examine the latest clinical data comparing ablation alone versus ablation plus immune therapy. Moderated by Elena Violari, the discussion evaluates efficacy, recurrence rates, and synergistic mechanisms, while exploring how cancer stage, tumor location, and genetic markers guide patient selection for these evolving treatment strategies. Moderator: • Elena Violari, MD | Loyola University Chicago Faculty: • Gentry King, MD | University of Washington • Isabel G. Newton, MD, PhD | University of California San Diego Resources Gentry King, MD https://www.fredhutch.org/en/provider-directory/gentry-king.html [https://www.fredhutch.org/en/provider-directory/gentry-king.html] Isabel G. Newton, MD, PhD https://providers.ucsd.edu/details/22369/radiology [https://providers.ucsd.edu/details/22369/radiology] Checkmate 90W Trial: https://ascopubs.org/doi/full/10.1200/JCO.22.01436 [https://ascopubs.org/doi/full/10.1200/JCO.22.01436] IMbrave150 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900800-6/fulltext [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900800-6/fulltext] LEAP-012 Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract] Emerald-Y90 Trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221 [https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221] Disclaimer This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.

Episode 3: Exploring the Role of (Neo)Adjuvant Immunotherapy Pre-Transplant vs. Adjuvant Immunotherapy Post-Transplant

Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice. Episode 3: Exploring the Role of (Neo)Adjuvant Immunotherapy Pre-Transplant vs. Adjuvant Immunotherapy Post-Transplant Should immunotherapy come before or after transplant? Experts Parissa Tabrizian and Beau Toskich explore one of the most critical questions in transplant oncology: when is the right time to introduce immunotherapy? Moderated by William Rilling, the discussion dives into the clinical evidence surrounding neoadjuvant and adjuvant immuno-oncology (IO) therapies in transplant settings. Moderator: • William Rilling, MD | Medical College of Wisconsin Faculty: • Beau Toskich, MD | Mayo Clinic • Parissa Tabrizian, MD | Mount Sinai Resources Beau Toskich, MD https://www.mayoclinic.org/biographies/toskich-beau-m-d/bio-20309020 [https://www.mayoclinic.org/biographies/toskich-beau-m-d/bio-20309020] Parissa Tabrizian, MD https://profiles.mountsinai.org/parissa-tabrizian [https://profiles.mountsinai.org/parissa-tabrizian] Emerald-Y90 Trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221 [https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221] STORM Trial: https://gut.bmj.com/content/68/6/1065 [https://gut.bmj.com/content/68/6/1065] LEAP-012 Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract] ImmunoXXL Trial: https://clinicaltrials.gov/study/NCT05879328 [https://clinicaltrials.gov/study/NCT05879328] IMbrave150 Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900800-6/fulltext [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900800-6/fulltext] Disclaimer This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.

Episode 2: Comparing LEAP-012 Study vs. EMERALD-1 Study

Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice. Episode 2: Comparing LEAP-012 Study vs. EMERALD-1 Study How will the LEAP-012 and EMERALD-1 studies shape the future of liver cancer treatment? Experts Riad Salem and Stephen Chan analyze key differences in trial design, methodology, and clinical outcomes. Moderated by Lead Moderator Venkatesh Krishnasamy with Co-Moderator Sean Golden, the discussion explores how these pivotal studies may influence patient selection, treatment sequencing, and the real-world application of evolving care protocols. Moderator: • Venkatesh Krishnamsamy, MD | University of Alabama Birmingham Co-Moderator: • Sean Golden, MD | University of Wisconsin Faculty: • Riad Salem, MD, MBA | Northwestern University • Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP, MD | Chinese University of Hong Kong Resources Riad Salem, MD, MBA https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=17542 [https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=17542] Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP, MD https://www.med.cuhk.edu.hk/staff/professor-chan-lam-stephen [https://www.med.cuhk.edu.hk/staff/professor-chan-lam-stephen] Emerald-Y90 Trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221 [https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221] LEAP-012 Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract] Disclaimer This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.

Episode 1: Local Therapy vs. Combination (Local + Systemic) Therapy

Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice. Episode 1: Local Therapy vs. Combination (Local + Systemic) Therapy Synopsis Should combination therapies redefine the standard of care in liver cancer? Experts Lingling Du and Christopher Malone examine the latest clinical evidence and debate the benefits and challenges of combining treatment modalities. Moderated by Edward Kim with Co-Moderator Cynthia De la Garza, the discussion analyzes efficacy, toxicity, cost, and patient selection criteria to determine which patients may benefit most from combination approaches. Moderator: • Edward Kim, MD | Mount Sinai Co-Moderator: • Cynthia De la Garza, MD | Mayo Clinic Faculty: • Lingling Du, MD | Ochsner Health • Christopher Malone, MD | WashU Medicine Resources Dr. Lingling Du, MD https://www.ochsner.org/doctors/lingling-du/ [https://www.ochsner.org/doctors/lingling-du/] Dr. Christopher Malone, MD https://physicians.wustl.edu/items/chris-malone/ [https://physicians.wustl.edu/items/chris-malone/] IMbrave050 Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00800-6/fulltext [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00800-6/fulltext] LEAP-012 Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract] Rowan Study: https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.TPS622 [https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.TPS622] Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma: https://gut.bmj.com/content/gutjnl/68/2/335.full.pdf [https://gut.bmj.com/content/gutjnl/68/2/335.full.pdf] Disclaimer This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.